Shares of Neuland Laboratories fell nearly 4% on Friday, August 1, closing at ₹12,761, after the company reported disappointing Q1FY26 results. The pharmaceutical firm posted a net profit of ₹13.90 crore, plunging 85.8% year-on-year compared to ₹97.87 crore in the same quarter last year. Revenue also declined sharply by 33.4% to ₹292.75 crore, down from ₹439.60 crore a year ago. Operationally, the company saw a contraction in its operating profit margin to 11.78%, from 28.06% in the June 2024 quarter. Profit before tax also fell significantly by 84% to ₹17.57 crore.
The sharp deterioration in profitability and sales performance triggered a sell-off in the stock, dragging it nearly 4% lower in early trade.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult your financial advisor before making any investment decisions.
